Screener
Assembly Biosciences ASMB Debt Securities Realized Gain Loss
Debt Securities Realized Gain Loss at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesRealizedGainLoss.
The source filing: Assembly Biosciences’s 10-K, filed March 19, 2026. Open the filing →
- Filed
- Mar 19, 2026, 4:15 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-115992
FAQ
- What is Assembly Biosciences's debt securities realized gain loss?
- Assembly Biosciences (ASMB) reported debt securities realized gain loss of $750 in Q4 2025.
- What does debt securities realized gain loss mean?
- This reflects the net gain or loss recognized upon the sale or maturity of debt securities held in the company's investment portfolio. It adjusts net income to reconcile with cash flow, as these gains or losses are non-operating in nature. Tracking this provides insight into the performance of the company's treasury management and investment strategy.
Ask your AI about Assembly Biosciences's debt securities realized gain loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude